Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study  by Di Lorenzo, Giuseppe et al.
Jones LN (2004) The hair fiber surface. In: Skin,
hair, and nails. Structure and function. (B
Forslind, Lindberg M, Norlen L, eds), chapter
12, New York: Marcel Dekker Inc, 285–317
Kligman AM (1963) The uses of sebum. Brit J
Dermatol 75:307–19
Lillywhite HB (2006) Water relations of tetrapod
integument. J Exp Biol 209:202–26
Maderson PFA (1972) When? Why? And how?
Some speculations on the evolution of
vertebrate integument. Am Zool 12:159–71
Maderson PFA (2003) Mammalian skin evolution:
a reevaluation. Exp Dermatol 12:233–6
Menon GK (2004) The skin barrier: an evolutionary
and environmental perspective. In: Skin, hair,
and nails. Structure and function. (Forslind B,
Lindberg M, Norlen L, eds), chapter 8, New
York: Marcel Dekker Inc, 189–216
Merrill BJ, Gat U, DasGupta R, Fuchs E (2001)
Tcf3 and Lef1 regulate lineage differentiation
of multipotent stem cells in skin. Genes Dev
15:1688–705
Montagna W, Parakkal PF (1974) Structure and funct-
ion of skin. 3rd ed. London: Academic Press
Oftedal OT (2002) The mammary gland and its
origin during synapsid evolution. J Mammary
Gland Biol Neoplasia 7:225–512
Philpott MP, Sander DA, Kealey T (1996) Is the
sebaceous gland important for inner root sheath
breakdown? Hair research for the next millen-
ium. Amsterdam: Elsevier Science BV, 393–5
Porter RM, Jahoda CAB, Lunny DP, Henderson G,
Ross J, McLean WH et al. (2002) Defollicu-
lated: a dominant mutation leading to poor
sebaceous gland differentiation and total
elimination of pelage follicles. J Invest
Dermatol 119:32–7
Prouty SM, Lawrence L, Stenn KS (1997) Fibro-
blast-dependent induction of a skin hamarto-
ma: murine lesion with similarity to human
nevus sebaceous of Jadassohn. Lab Invest
76:179–89
Rothman S (1954) Physiology and biochemistry of
the skin. Chicago: University Chicago Press,
284–5
Ruben JA, Jones TD (2000) Selective factors
associated with the origin of fur and feathers.
Am Zool 40-:585–96
Silva-Vargas V, Celso CL, Giangreco A, Ofstad T,
Prowse DM, Braun KM et al. (2005) Beta-
catenin and hedgehog signal strength can
specify number and location of hair follicles
in adult epidermis without recruitment of
bulge stem cells. Develop Cell 9:121–31
Sokolov VE (1982) Mammal skin. University
California Press: Berkeley, CA
Stenn KS, Cotsarelis G, Price VH (2006) Report
from the cicatricial alopecia colloquium.
J Invest Dermatol 126:539–41
Sundberg JP, Bogess D, Sundberg BA,
Eilertsen K, Parimoo S, Filippi M et al. (2000)
Asebia-2J (Scd1ab2J): a new allele and a
model for scarring Alopecia. Am J Path 156:
2067–75
Vidal VPI, Chaboissier M-C, Luzkendorf S, Cotsar-
elis G, Mill P, Hui C-C et al. (2005) Sox9 is
essential for outer root sheath differentiation
and the formation of the hair stem cell
compartment. Current Biol 15:1340–51
Wheatley VR (1986) The Sebaceous glands. In:
The physiology and pathophysiology of the
skin. (Jarrett A, ed), vol. 9. London: Academic
Press, 2705–21
Williams D, Stenn KS (1994) Transection level
dictates the pattern of hair follicle sheath
growth in vitro. Dev Biol 165:469–79
Wrench R, Hardy JA, Spearman RIC (1980)
Sebokeratocytes of avian epidermis—with
mammalian comparisons. In: The skin of
vertebrates (Spearman IC, Riley PA, eds),
New York: Academic Press, 47–55
Wu P, Hou L, Plikus M, Hughes M, Scehnet J,
Suksaweang S et al. (2004) Evo-Devo of
amniote integuments and appendages. Int J
Dev Biol 48:249–70
Zouboulis CC, Eady A, Philpott M, Goldsmith LA,
Orfanos C, Cunliffe WC et al. (2005) What is
the pathogenesis of acne? Exp Dermatol
14:143–52
Activity and Safety of Pegylated Liposomal Doxorubicin as
First-Line Therapy in the Treatment of Non-Visceral Classic
Kaposi’s Sarcoma: A Multicenter Study
Journal of Investigative Dermatology (2008) 128, 1578–1580; doi:10.1038/sj.jid.5701215; published online 10 January 2008
TO THE EDITOR
While several studies have been pub-
lished regarding AIDS-related Kaposi’s
sarcoma (KS), and standard first- and
second-line treatments exist for those
patients (Di Lorenzo et al., 2007), no
such standard treatment has been es-
tablished for Classic KS (CKS). Two
randomized trials showed that pegy-
lated liposomal doxorubicin (PLD) is
more effective than the doxorubicin–-
bleomycin–vincristine combination
(Northfelt et al., 1998) and the bleomy-
cin–vincristine combination (Stewart
et al., 1998). Although PLD has been
approved for use in patients with AIDS-
associated KS, only a few case reports
and small retrospective studies have
described the use of PLD in CKS
(Gottlieb et al., 1997; Kreuter et al.,
2005; Di Trolio et al., 2006; Ezquerra
et al., 2006; Di Lorenzo et al., 2008).
We conducted an international multi-
center retrospective analysis to evaluate
the activity and safety of PLD in patients
with CKS who had not received pre-
vious systemic chemotherapy.
Between 1998 and 2007, eight
institutions treated 55 patients with
CKS with PLD, as first-line chemothe-
rapy. Median age was 70 years and 15
patients (27%) were older than 75 years
(Table 1). A total of 610 cycles of PLD
were administered. The schedule of
every 3 weeks resulted in a mean
received dose intensity of 19.2mgm2,
or 96% of the planned dose intensity.
A dose reduction of 20% was made
in 70 cycles (12%) because of grade 3
neutropenia, anemia, or thrombo-
cytopenia. The median number of
cycles administered was nine (range,
3–30).
Complete and major responses were
observed in 16 (29%) and 23 (42%)
patients, respectively, giving an overall
response rate of 71%. Minor response
was observed in 6 (11%), whereas
stable disease and disease progression
occurred in six (11%) and four (7%)
patients, respectively. Median time to
response was 4 months (range, 1.4–7
months) and median duration of res-
ponse was 25 months (range, 1–55
months). There was a statistically sig-
nificant correlation between complete
response and baseline stage. In fact,Abbreviations: CKS, Classic KS; KS, Kaposi’s sarcoma; PLD, pegylated liposomal doxorubicin
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54% of the complete responses were
observed in stage II, whereas only 15%
were in stage III, and none in stage IV
(Po0.05). The median progression-free
survival was 30 months (95% confi-
dence interval, 4–60 months). At a
median follow-up of 50 months (95%
confidence interval, range 7–108
months), 43 patients were alive and
12 had died (four KS-related and eight
non-KS-related deaths). Remission of
pain and lymphedema were recorded
in eight (40%) and nine (53%) patients
after six cycles, respectively. Hemor-
rhage, functional impairment, ulcera-
tion, and lymphorrhea resolved in 43,
78, 63, and 40% of patients, respec-
tively.
All 55 patients were assessable for
treatment safety. In general, treatment
was well tolerated and no toxic deaths
occurred. The most important grade 3
toxicities included neutropenia in nine
cases (16%), nausea/vomiting (5.5%),
thrombocytopenia (3.6%), and hand–-
foot syndrome (5.5%). Grade 4 toxicity
was limited to neutropenia (5.5%)
requiring granulocyte-colony stimulat-
ing factor and anemia (3.6%) requiring
transfusions (Table 2).
This study of 55 patients with CKS
represents the largest study of PLD in
CKS, as well as the largest study of any
cytotoxic agent in this setting. Our
overall response rate (71%) in pre-
viously untreated CKS compares favor-
ably with that observed in a PLD study
in AIDS–KS (45.9%) (Northfelt et al.,
1998). Two other studies investigated
the role of PLD in CKS. In a retro-
spective study by Kreuter et al. (2005),
PLD was compared with IFN-a as
second-line therapy for CKS, and in an
analysis by Di Lorenzo, PLD was
administered to patients with previously
treated CKS (Di Lorenzo et al., 2008).
Eight of 12 (67%) CKS patients treated
with PLD by Kreuter achieved a com-
plete or major response. In that trial, six
patients were treated with IFN-a, with
major response in 17%. The difference
in response to treatment between PLD
and IFN-a was significant (Po0.05). In
the Di Lorenzo study, 20 men with
previously treated CKS received PLD.
Complete and partial responses were
observed in two (10%) and 14 (70%)
patients, respectively. Fourteen patients
(70%) achieved remission of tumor-
associated pain/edema after six cycles.
To our knowledge, long follow-up
of patients with CKS has not been
previously reported. In our study,
we demonstrate that PLD can control
disease for more than 2 years. We did
not observe cardiac side effects. Our
Table 1. Patient characteristics
No. of patients 55
Age (years) 70 (31–88)
o75 years 40 (73%)
475 years 15 (27%)
WHO performance status
0 30 (55%)
1 25 (45%)
Sex
Male 38 (69%)
Female 17 (31%)
Ethnic background
South/Mediterranean European 27 (49%)
Eastern European 12 (22%)
North European 6 (11%)
Western European 10 (18%)
Race
White 55 (100%)
Black 0
Cutaneous stage
II 24 (44%)
III 20 (36%)
IV 11 (20%)
Previous therapy
Intralesional vinblastine 13 (24%)
Radiotherapy 2 (4%)
Surgery 2 (4%)
Cryotherapy 3 (5%)
Complications 30 (55%)
Pain 20 (36%)
Edema 17 (31%)
Hemorrhage 14 (25%)
Functional impairment 9 (16%)
Ulcerations 8 (15%)
Lymphorrhea 5 (9%)
Type of pain medication administered (20 pts)
Minor analgesics 12 (60%)
Mild narcotics 4 (20%)
Strong narcotics 4 (20%)
Data are expressed as median (range).
WHO: World Health Organization. Pain medication recorded according to WHO ladder.
Cutaneous staging system based on objective criteria (Brambilla, 2003).
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findings need to be confirmed in a
prospective study, which, owing to the
rarity of the disease, would require the
participation of many more centers. It
would be interesting to evaluate the
action of PLD, comparing it with active
and well-tolerated strategies such as
vinblastine alone, vinblastine/bleomy-
cin, or taxanes.
The eligibility criteria for this study
included the following: histologically
confirmed KS, agep90 years, World
Health Organization performance sta-
tus 0 or 1, negative HIV serology, and
no immunosuppressive therapy. Pa-
tients were excluded if there was
evidence of visceral involvement, pre-
vious systemic chemotherapy, uncon-
trolled chronic disease not related to
KS, or history of previous cancer.
Patients with the following stages
(Brambilla et al., 2003) were eligible:
stage II A (infiltrating) slow variant if
tumor-related complications were present
(lymphedema, hemorrhage, pain, func-
tional impairment, ulcerations); stage II B
rapid variant; stage III (florid); and stage IV
(disseminated). Patients were treated with
PLD (20mgm2) (Caelyx, Schering-
Plough, Milan, Italy; Doxil, OrthoBiotech,
New Jersey) every 3 weeks intravenously
until disease progression or irreversible
toxicity was observed.
The primary end point was objective
response rate. Secondary end points
were toxicity, improvement in tumor-
related symptoms, time to progression,
and overall survival. Complete res-
ponse was the absence of detectable
lesions lasting for at least 8 weeks.
Major response wasX50% decrease in
the number of measurable lesions and
absence of new cutaneous lesions. The
sum of complete and major responses
represented overall response rate. Min-
or response was 25–50% decrease in
the number of lesions. Progressive
disease was the appearance of new
lesions, 425% increase in previous
lesions, or worsening of tumor-asso-
ciated complications. Stable disease
was defined as any response that did
not fulfilling the criteria described above.
We also evaluated reductions in tumor-
associated complications (including
pain, edema, ulceration, hemorrhage,
functional impairment, and lymphor-
rhea). Treatment-related toxicity was
evaluated using the National Cancer
Institute Common Toxicity Criteria (ver-
sion 3.0). Patient consent was deemed
not necessary, as the authors were
reviewing their own patients’ charts.
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Table 2. Toxicity for 55 patients (%)
Toxicity Grades 1–2 Grade 3 Grade 4
Neutropenia 26% 16% 5.5%
Anemia 7.2% 1.8% 3.6%
Thrombocytopenia 11% 3.6% 0
Nausea/vomiting 20% 5.5% 0
Hand–foot syndrome 18% 5.5% 0
Fatigue 9% 3.6% 0
Peripheral neuropathy 13% 1.8% 0
Stomatitis 13% 3.6% 0
Liver dysfunction 5.5% 1.8% 0
Alopecia 15% 2% 0
Constipation 9% 0 0
Diarrhea 7.2% 0 0
Nephrotoxicity 3.6% 0 0
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